Xenetic Biosciences, Inc. (XBIO): Nasdaq/NYSE listing notice — Xenetic Biosciences receives Nasdaq extension to May 29, 2023 to regain $1 bid price compliance

Xenetic Biosciences, Inc.

Nasdaq granted an additional 180 calendar days, until May 29, 2023, to meet the $1.00 minimum bid price requirement.
Company previously notified of non-compliance on June 3, 2022; bid price below $1.00 for 30 consecutive business days.
Eligibility based on meeting all other initial listing standards and written intent to cure via reverse stock split if needed.
If bid price closes at $1.00+ for 10 consecutive days before May 29, 2023, compliance will be achieved.
Failure to cure may lead to delisting, subject to appeal to a Nasdaq hearings panel.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Xenetic Biosciences, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: extension granted
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 1, 2022, the Company received a letter from Nasdaq informing it that although the Company’s common stock has not regained compliance with the minimum $1.00 bid price per share requirement, Nasdaq has determined that the Company is eligible for an additional 180 calendar day period, or until May 29, 2023, to regain compliance. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requireme

View on SEC.gov

8 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Xenetic Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001683168-22-008170

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.